Dose-response : a publication of International Hormesis Society · 2020
Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hu Xingsheng, Hu Chunhong, Zhong Ping, Wen Yajing, Yang Yong, Chen Juan, Chen Xiangyu
Аннотация
OBJECTIVE: To compare the efficacy of 3/4-drugs' group with 1-drug's or 2-drugs' groups in coronavirus disease 2019 (COVID-19).
METHODS: We included 207 patients confirmed with COVID-19. We compared the viral clearance rate and discharge rate at day 7, 14, 21 and 28, and median time of viral clearance and length of hospitalization in patients treated with 3/4, 1 or 2 drugs.
RESULTS: The viral clearance rates of the 3/4-drugs group at day 7, 14 and 21 were significantly lower than those in the 1-drug's or 2-drugs' groups (P < 0.05). The median viral clearance days in 3/4-drugs group (13.5 days) were longer than 1-drug's or 2-drugs' groups (both were 9 days) (P < 0.001). The patients' discharge rates in the 3/4-drugs group at day 14 and 21 were significantly lower than that in the 1-drug's or 2 drugs' group (P < 0.05). The median length of hospitalization in the 3/4-drugs group was 17 days, which was significantly longer than 11 days in the 1-drug group and 13 days in the 2-drug group (P < 0.05).
CONCLUSION: The efficacy of 1 or 2 antiviral drugs was similar in COVID-19, and 3/4-drug regimens were not associated with clinical improvement. Corticosteroid treatment and more serious disease were also risk factors for viral clearance and patients'discharge.
METHODS: We included 207 patients confirmed with COVID-19. We compared the viral clearance rate and discharge rate at day 7, 14, 21 and 28, and median time of viral clearance and length of hospitalization in patients treated with 3/4, 1 or 2 drugs.
RESULTS: The viral clearance rates of the 3/4-drugs group at day 7, 14 and 21 were significantly lower than those in the 1-drug's or 2-drugs' groups (P < 0.05). The median viral clearance days in 3/4-drugs group (13.5 days) were longer than 1-drug's or 2-drugs' groups (both were 9 days) (P < 0.001). The patients' discharge rates in the 3/4-drugs group at day 14 and 21 were significantly lower than that in the 1-drug's or 2 drugs' group (P < 0.05). The median length of hospitalization in the 3/4-drugs group was 17 days, which was significantly longer than 11 days in the 1-drug group and 13 days in the 2-drug group (P < 0.05).
CONCLUSION: The efficacy of 1 or 2 antiviral drugs was similar in COVID-19, and 3/4-drug regimens were not associated with clinical improvement. Corticosteroid treatment and more serious disease were also risk factors for viral clearance and patients'discharge.